We found that DRD2 expression levels in lung cancer cell lines and normal MRC5 were nearly the same before treatment; nevertheless, after cell treatment with drugs, the expression levels of this receptor altered and when it was exposed to BRC, the expression levels of this receptor in cancer cells compared to normal MRC5 increased significantly and after treatment with targeted nano drag, particularly in QU-DB cells, a further increase was observed. The gene discussed is DRD2; the disease is lung cancer.